About: Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency
Creator	Adebayo, Adebola Icenogle, Joseph Perelygina, Ludmila Seppänen, Mikko Hautala, Timo Sullivan, Kathleen
source	Elsevier; Medline; PMC
abstract	Abstract Persistent rubella virus (RV) infection has been associated with various pathologies such as congenital rubella syndrome, Fuchs's uveitis, and cutaneous granulomas in patients with primary immune deficiencies (PID). Currently there are no drugs to treat RV infections. Nitazoxanide (NTZ) is an FDA-approved drug for parasitic infections, and has been recently shown to have broad-spectrum antiviral activities. Here we found that empiric 2-month therapy with oral NTZ was associated in the decline/elimination of RV antigen from lesions in a PID patient with RV positive granulomas, while peginterferon treatment had no effect. In addition, we characterized the effects of NTZ on cell culture models of persistent RV infection. NTZ significantly inhibited RV replication in a primary culture of human umbilical vein endothelial cells (HUVEC) and Vero and A549 epithelial cell lines in a dose dependent manner with an average 50% inhibitory concentration of 0.35 μg/ml (1.1 μM). RV strains representing currently circulating genotypes were inhibited to a similar extent. NTZ affected early and late stages of infection by inhibiting synthesis of cellular and RV RNA and interfering with intracellular trafficking of the RV surface glycoproteins, E1 and E2. These results suggest a potential application of NTZ for the treatment of persistent rubella infections, but more studies are required.
has issue date	2017-11-30(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2017.09.019
bibo:pmid	28974385
has license	els-covid
sha1sum (hex)	ec408739d9a284c326bc57a0699c293356df6e6c
schema:url	https://doi.org/10.1016/j.antiviral.2017.09.019
resource representing a document's title	Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency
has PubMed Central identifier	PMC7127570
has PubMed identifier	28974385
schema:publication	Antiviral Research
resource representing a document's body	covid:ec408739d9a284c326bc57a0699c293356df6e6c#body_text
is schema:about of	named entity 'IMMUNE DEFICIENCY' named entity 'BROAD' named entity 'genotypes' named entity 'elimination' named entity 'PID' named entity 'models' named entity 'rubella virus' named entity 'TREATMENT' named entity 'AND LATE' named entity '0.35' named entity 'PATIENTS' named entity 'MONTH' named entity 'ASSOCIATED' named entity 'INHIBITED' named entity 'AFFECTED' named entity 'FOUND' named entity 'DEPENDENT' named entity 'GLYCOPROTEINS' named entity 'INTRACELLULAR' named entity 'RECENTLY' named entity 'INFECTIONS' named entity 'ASSOCIATED WITH' named entity 'REPLICATION' named entity 'GRANULOMAS' named entity 'VARIOUS' named entity 'GENOTYPES' named entity 'FUCHS' named entity 'PID' named entity 'PRIMARY CULTURE' named entity 'CONCENTRATION OF' named entity 'PERSISTENT' named entity 'HERE' named entity 'SPECTRUM' named entity 'VIRUS REPLICATION' named entity 'POSITIVE' named entity 'EARLY' named entity 'EXTENT' named entity 'HAVE' named entity 'THERAPY' named entity 'APPLICATION' named entity 'DRUG' named entity 'CELLULAR' named entity 'SPECTRUM' named entity 'CUTANEOUS' named entity 'HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS' named entity 'PATHOLOGIES' named entity 'DECLINE' named entity 'SYNTHESIS' named entity 'PARASITIC' named entity 'POTENTIAL' named entity 'ACTIVITIES' named entity 'UVEITIS' named entity 'APPROVED' named entity 'THESE' named entity 'ADDITION' named entity 'EMPIRIC' named entity 'INHIBITING' named entity 'TRAFFICKING' named entity 'REQUIRED' named entity 'PATIENT' named entity 'INHIBITION' named entity 'DRUG' named entity 'CELL CULTURE' named entity 'RUBELLA VIRUS' named entity 'BROAD' named entity 'RESULTS' named entity 'SIMILAR' named entity 'STUDIES' named entity 'AVERAGE' named entity 'DRUGS' named entity 'TREAT' named entity 'NO EFFECT' named entity 'VERO' named entity 'ANTIVIRAL' named entity 'NITAZOXANIDE' named entity 'RNA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software